Lupin reports Rs 438.25 crore net profit in Q3

Published On 2021-01-30 03:30 GMT   |   Update On 2021-01-30 03:31 GMT

New Delhi: Pharma major Lupin has reported a consolidated net profit of Rs 438.25 crore for the quarter ended December 31, 2020.

The company had posted a net loss of Rs 835 crore for the corresponding period of the previous fiscal, Lupin said in a late night filing to the BSE.

Consolidated revenue from operations of the company stood at Rs 3,917.30 crore for the quarter under consideration. It was at Rs 3,716.09 crore for the same period a year ago, it added.

Read also: Alembic Pharma Net profit rises 25 percent to Rs 293 crore in Q3

"We continue our trajectory of improved profitability and sustainable business growth. All our major businesses delivered robust growth amidst pandemic-related challenges and a weak flu season, reflecting the resilience of our business", Lupin Ltd MD Nilesh Gupta said.


Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News